"C-Peptide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin.
Descriptor ID |
D002096
|
MeSH Number(s) |
D06.472.699.587.200.500.250 D12.644.548.586.200.500.250
|
Concept/Terms |
C-Peptide- C-Peptide
- C Peptide
- Connecting Peptide
- Proinsulin C-Peptide
- Proinsulin C Peptide
- C-Peptide, Proinsulin
- C Peptide, Proinsulin
|
Below are MeSH descriptors whose meaning is more general than "C-Peptide".
Below are MeSH descriptors whose meaning is more specific than "C-Peptide".
This graph shows the total number of publications written about "C-Peptide" by people in this website by year, and whether "C-Peptide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2008 | 1 | 0 | 1 |
2011 | 0 | 1 | 1 |
2012 | 0 | 1 | 1 |
2016 | 0 | 1 | 1 |
2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "C-Peptide" by people in Profiles.
-
Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes. Diabetes Obes Metab. 2017 06; 19(6):866-873.
-
Sfrp5 associates with beta-cell function in humans. Eur J Clin Invest. 2016 Jun; 46(6):535-43.
-
Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial). PLoS One. 2012; 7(3):e33108.
-
Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial. PLoS One. 2011 Mar 11; 6(3):e17554.
-
Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes. 2008 Apr; 57(4):929-37.